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ABSTRACT. 
 
Background. The present work illustrates how magnetic separation-based blood 
purification using ultra-strong iron nanomagnets can be implemented into an 
extracorporeal blood purification circuit. By this promising technique, today’s blood 
purification may be extended to specifically filter high molecular compounds without 
being limited by filter cut-offs or column surface saturation. Methods. Blood spiked with 
digoxin (small molecule drug) and interleukin-1β (inflammatory protein) was circulated 
ex vivo through a device composed of FDA-approved blood transfusion lines. Target-
specific nanomagnets were continuously injected and subsequently recovered by the aid 
of a magnetic separator before re-circulating the blood. Results. Magnetic blood 
purification was successfully carried out under flow conditions: Already in single-pass 
experiments, removal efficiencies reached values of 75% and 40% for digoxin and 
interleukin-1β. Circulating 0.5 L of digoxin-intoxicated blood in a closed loop, digoxin 
concentration was decreased from initially toxic to therapeutic concentrations within 30 
minutes and purification extents of 90% were achieved after 1.5 hour. Conclusions. 
Magnetic separation can be successfully implemented into an extracorporeal blood 
purification device. Simultaneous and specific filtering of high molecular compounds 
may offer promising new therapeutic tools for the future treatment of complex diseases 
such as sepsis and autoimmune disorders. 
 
KEY WORDS detoxification, dialysis, magnetic separation, nanoparticle, selective, 
therapy 
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SHORT SUMMARY 
We present a first proof of concept of magnetic separation-based blood purification 
highlighting new capacities of this technology for a fast and highly selective removal of 
target compounds from human whole blood. Based on this promising new approach, 
today’s blood purification may be extended to specifically filter both low- and high-
molecular compounds without being limited by filter cut-offs or column surface 
saturation. 
 
INTRODUCTION. 
 
New mechanistic insights into complex diseases (sepsis, autoimmune disorders) allow for 
the identification of potential new therapeutic targets and make high demands on today’s 
blood purification techniques (1, 2). Despite remarkable achievements of current blood 
purification systems, target-specific filtering of multiple compounds remains a major 
issue, particularly for molecules differing in physiochemical character (i.e. mass, size, 
charge) and high-molecular weight compounds, such as proteins. Where diffusion is slow 
(large target molecules) and filtration is not appropriate (e.g. due to filter cut offs), 
patients require (centrifugal) plasma exchange (loss of plasma, risk of transfusion 
reactions) or blood purification through adsorbents. New technologies, such as antibody 
coated adsorbents (3) or microsphere-based detoxification systems (MDS) (4, 5) are now 
being introduced to specifically aim at therapeutic targets. The use of spherical non-
porous particles as adsorbents has been shown to benefit from the intrinsically better 
surface accessibility (no pore diffusion) due to higher external surface areas and shorter 
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diffusion distances compared to membranes (6). Most recently, we introduced the 
concept of magnetic blood purification using target-specific metal nanomagnets to 
selectively and efficiently remove toxins from whole blood in small volume batches (7). 
In this approach, ligands (e.g. antibodies) immobilized on tiny free flowing magnetic 
particles specifically capture noxious compounds. By applying external magnetic 
gradient fields, the toxin-loaded nanomagnets can be immediately separated and removed 
from the blood. 
To bring this promising technology one step closer to clinical application, a first 
implementation into a continuously operating extracorporeal circuit was developed. 
Target-specific (e.g. antibody-functionalized) metal nanomagnets are continuously 
injected into a continuous blood flow where they specifically capture the desired 
compounds. Subsequent removal of the pathogen-loaded nanomagnets from the blood 
stream by continuous magnetic separation allows recirculation of the purified blood. In 
order to demonstrate the potential of this new approach to remove molecules completely 
differing in character, digoxin and interleukin-1 (IL-1) were used as model compounds 
(7). Digoxin (MW 780 g/mol) is a typical representative of a small molecule drug with a 
narrow therapeutic window. In contrast, the much larger interleukin-1 (MW 17 000 
g/mol) is a pro-inflammatory protein. Among other cytokines, it plays a crucial role in the 
orchestration of inflammatory processes, such as infections (8). Digoxin- and IL-1- 
antibodies were anchored on the carbon surface of highly magnetic carbon coated metal 
nanomagnets and applied as capturing moieties. Using these two model compounds, we 
demonstrate how magnetic separation can be successfully implemented into an 
extracorporeal blood purification device allowing for fast and efficient clearance rates. 
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This raises attractive opportunities for future therapeutic strategies, where we rather 
remove a noxious compound from a patient’s blood than attempting a treatment through 
addition of another compound (i.e. drug) to counteract the negative effect of the 
pathogen. 
 
MATERIALS AND METHODS. 
 
Synthesis of Target-specific Nanomagnets. Carbon coated iron nanoparticles of 
core/shell geometry (C/Fe, mean diameter 30 nm, saturation magnetization 150 emu/g, 
specific surface area 30 m2/g) were manufactured and washed in acid solution (1 week in 
HCl, 24 vol%) prior to use in order to dissolve incompletely coated particles following 
previously reported procedures (6, 7). The nanomagnets were employed to magnetically 
tag digoxin antibody fragments (Beacon Pharmaceuticals Ltd, Kent, UK), and human 
interleukin-1β (IL-1β) antibodies (eBioscience, Inc. San Diego, USA). 
Anti-digoxin-functionalized nanomagnets (C/Fe-anti-digoxin) were obtained via a 
stepwise procedure as previously reported (7): Briefly, anti-digoxin fragments were 
covalently linked to an amine-reactive crosslinker (MAL-dPEG24-NHS ester, Quanta 
Biodesign, Powell, OH 43065 USA) on the NHS end. Subsequently the FAB-crosslinker 
complex was covalently bound to thiol-functionalized nanomagnets. 
For the synthesis of anti-interleukin-1 nanomagnets (C/Fe-anti-IL-1), interleukin-1 
antibody was tagged by the aid of a third-party compound: Streptavidin (Leinco 
Technologies, Inc. St. Louis, USA) was first physisorbed on the nanomagnets’ outer 
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shells. Biotinylated anti-human IL-1β was then anchored onto the streptavidin covered 
nanomagnets.  
Magnetically tagged agents were stocked in hydroxyethyl starch (Tetraspan 6%, B.Braun 
Medical AG, Sempach, Switzerland, containing hydroxyethylstarch 6%), and 
ultrasonicated for short periods (< 3 min) before usage. Good dispersion stability was 
achieved up to nanomagnet concentrations of 5 mg/mL (see Supplementary Materials). 
Nanomagnet concentrations in the used dispersions were kept as high as possible in order 
to minimize the volume added to the blood. 
Blood. Blood for experiments was withdrawn from healthy volunteers and stabilized with 
sodium heparin (25000 units / 5 mL, B. Braun Medical AG) at 250 units / mL. Blood 
used in continuous experiments (500 mL) was purchased from Blutspende Zürich (8952 
Schlieren, Switzerland) as separate bags of freshly frozen plasma (FFP, A+) and 
erythrocyte concentrate (EC, A+) and then reconstituted. 
Construction of a device for continuous magnetic blood purification. An extracorporeal 
circuit was assembled of FDA-approved transfusion sets (Dispomed, Gelnhausen, 
Germany) as follows: A line equipped with a silicon injection port and a 10 mL chamber 
(art. 51800) was connected to extension lines (art. 51130), all lines having inner 
diameters of 3 mm. To drive fluid flow, two different peristaltic pumps were used: 
REGLO Digital (Ismatec SA) for pumping the particle dispersion and a hemofiltration-
approved pump head supplied by Infomed SA (Geneva, Switzerland) for the blood flow. 
During experiments, the nanoparticle dispersion container was kept shaking while 
pumped. Dosing was kept constant over time in order to grant a constant concentration of 
nanomagnets in the device.  
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A multi-line injection system was developed in order to inject the nanoparticle 
dispersion. Tygon standard tubing (R-3607, 0.27 mm, Ismatec SA, Glattbrugg, 
Switzerland) was slipped onto stainless steel cannulas (Ismatec SA, art.ISM 581), which 
were then used as injection nozzles collocating them into the injection port by 
perforation.  
For the magnetic separation, the blood purification line was passed through a magnetic 
separator (average field intensity ~ 0.5 T). High field gradients within the tubing were 
achieved by using an assembly of magnetized steel wires as initially proposed by 
Bockenfeld et al. (9) (detailed description in Supplementary Materials). Nanomagnets 
were subject to intense gradient fields which made them gradually deviate from the blood 
flow trajectory and eventually stick to tubing walls.  
Sample collection. Single pass pathogen removal efficiencies were determined by 
collecting freshly purified blood via a three-way connector (Dispomed Witt oHG, art. 
70017) after the magnetic separator (open loop configuration). Samples for the 
continuous blood purification experiments were withdrawn from the mixed blood 
reservoir, where the contaminant concentration only gradually lowered over time (closed 
loop configuration). 
Chemical analyses. Digoxin concentration was measured by the clinical chemistry 
laboratory in the University Hospital Zurich. The lower limit of detection was 0.2 
nmol/L. Interleukin-1β concentrations were measured in duplicate by commercial 
enzyme-linked immunosorbent assays (ELISA) (BD Biosciencies, 4123 Allschwil, 
Switzerland) at a lower limit of detection of 1 pg/mL.  
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Theoretical estimate for clearance efficiency. The theoretical pathogen removal 
efficiency was calculated assuming constant per-pass removal efficiency and an ideally 
mixed blood reservoir (homogeneous toxin concentration in the tank). The corresponding 
equation describing the evolution of the toxin concentration in the blood reservoir is 
given below. The concentration is denoted C and C0 is the initial concentration of the 
noxious compound in the tank. 

 T
R
V
txV
eCC 0            
t is the time elapsed from the beginning and τ denotes the cycle time. The ratio t/τ equals 
the number of cycle runs through the purification unit. VR and VT are the extracorporeal 
and the total volume, respectively, and x is a fixed per-pass-removal (toxin concentration 
in the blood leaving the extracorporeal device relative to the toxin concentration entering 
the device). A brief derivation of the clearance equation can be found in the 
Supplementary Materials. 
 
RESULTS. 
 
Assembly of a magnetic blood purification device. A first prototype device of magnetic 
separation-based continuous extracorporeal blood purification was assembled from three 
parts: 1) an injection port for nanomagnet administration into the blood stream, 2) a 
contact chamber where nanomagnets bind to the target molecules, and 3) a separator unit 
using magnetic field gradients to remove the pathogen-loaded nanomagnets from the 
blood before recirculation (Figure 1).  
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Continuous Injection of Nanomagnets into the Blood Stream. To overcome limitations of 
surface saturation that impair frequent changes of sorbent cartridges in today’s blood 
purification, a continuous administration of nanomagnets with vacant binding sites is 
crucial. To address this issue, an injector having multiple injection ports for continuous 
administration of fresh nanomagnets was developed. Multiple nanomagnet dispersions 
with different target specificity can be simultaneously connected to the injector and fed 
into the blood flow at different rates (Figure 1).  
Magnetic nanoparticles with a metallic core were used to achieve optimal particle 
separation after treatment. The use of metal nanomagnets gives access to superior 
magnetic properties (3 to 10 times higher saturation magnetization than traditional iron 
oxide based nanoparticles), but entrains increased agglomeration due to magnetic dipole-
dipole interactions. To prolong dispersion stability, various (protein or biopolymer 
containing), FDA-approved products for intravenous injection were evaluated for the 
dispersion of the nanomagnets. Among the polymer-based physiological solutions, 
hydroxy-ethyl starch turned out to be most effective to ensure stable dispersions (≤ 5mg 
nanomagnets/mL) while maintaining binding site accessibility (Figure 1).  
Nanomagnet-Blood Contact Chamber. After injection of nanomagnets into the 
extracorporeal blood circuit, blood contact (area, time) is crucial as it is immediately 
linked to the extraction efficiency. In order to ensure a homogeneous concentration of 
nanomagnets in the blood and to increase nanomagnet-blood contact time (and thus time 
for binding), drip chambers of the transfusion sets with a volume of 10 mL each were 
employed as contact chamber(s) (Figure 1). The number of contact chambers connected 
allowed for controlling the exact contact time between particles and blood. 
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Magnetic Separator – Continuous Separation of Nanomagnets from the Blood Stream. 
Finally, a high efficiency magnetic separator assembled according to a concept initially 
described by Bockenfeld et al. (9) was used as a continuously operating magnetic 
separation unit (Figures 2). The extracorporeal circuit was passed through the separation 
unit multiple times (4x) in order to ensure complete particle separation before blood 
recirculation (see Figure 2).  
 
Ex vivo Blood Circulation Setting. For continuous blood purification experiments, blood 
was filled into a reservoir (tank with a volume of 1 L, Figure 1) and circulated through 
the device using an approved peristaltic pump at 15 mL/min, which has earlier been 
described to be a feasible flow rate in an in vitro hemodialysis model (10). Particle 
sedimentation was minimal at this flow rate with still reasonably high nanomagnet/blood 
contact time. FDA-approved transfusion lines were assembled into an extracorporeal 
circuit with a total volume of 50 mL (disposable parts) and volume between nanomagnet 
injection point and magnetic separator of 30 mL. With the overall flow rate of 15 mL/min 
the corresponding blood-nanomagnet contact time in the extracorporeal circuit was two 
minutes. Based on the results obtained in batch experiments (see Supplementary 
Materials and an earlier study (7)), 0.5 mg of nanoparticles per mL of blood were applied 
for both digoxin and IL-1 removal. To demonstrate continuous magnetic blood 
purification, in vitro blood purification runs were performed using both open (Figure 3) 
and closed loop circuits (Figure 4). 
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Single Pass Blood Purification (ex vivo). Figure 3 reports results of single passes 
through the magnetic blood purification device (open loop configuration, blood passes 
the device only once). The removal efficiency was determined in samples withdrawn 
directly after the separator unit. Significant purification efficiencies were achieved under 
continuous conditions: 66 % and 38 % for digoxin and IL-1β, respectively. For digoxin, a 
blood sample (60 mL) was collected after a first pass purification and subjected to a 
second purification cycle (re-addition of fresh nanomagnets with vacant binding sites). 
Again, purification efficiencies of 70% were achieved using the same nanoparticle dose 
(0.5 mg/mL) (Figure 3). 
 
Continuous ex vivo Blood Purification. In order to simulate a more realistic scenario, 
blood purification was operated under continuous mode where the purified blood was re-
circulated into the blood reservoir after leaving the separation unit (closed loop 
configuration). Continuous treatment was conducted on 500 mL of digoxin-spiked blood 
(5.7 nmol/L). One additional mixing chamber was added to the circuit in order to enlarge 
effective contact time to 2.5 minutes while maintaining a standard flow rate of 15 
mL/min. With respect to the imposed dilution constraint (≤ 20%), overall 100 mL of 
dispersion of FeC-anti-digoxin (5mg/mL) were allowed to be injected over a time span of 
90 minutes (steady concentration of 0.38 mg of nanoparticles / mL). Samples withdrawn 
after the separator after the first two minutes of operation allowed for evaluation of an 
initial single pass removal efficiency of 75 %. In the following, samples were taken every 
4 minutes from the blood reservoir (Figure 4). After 30 minutes, digoxin concentration 
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was halved and reduced below toxic levels. One hour later, the treatment was ended at a 
final purification extent of 89 %. 
Theoretical Clearance Efficiency. The theoretical purification level was calculated based 
on the assumptions of an ideally mixed blood reservoir (homogeneous concentration) and 
a constant fraction of digoxin being removed in every pass (constant single pass removal 
efficiency). The calculated removal efficiency as a function of time is shown in Figure 4 
as a red line and compared to the experimental data.  
 
DISCUSSION. 
 
We present a first implementation of magnetic separation-based blood purification (7) 
into a continuously operating extracorporeal blood purification device. The feasibility of 
magnetic blood purification using functionalized metal core nanomagnets is proven in ex 
vivo experiments demonstrating remarkably high removal efficiencies which are very 
promising regarding future treatment in clinically critical situations. The prototype device 
for magnetic blood purification consists of a disposable unit (conventional FDA-
approved transfusion set) where the blood circulates just as in standard blood purification 
systems. Magnetic separation-specific items, such as the nanomagnet injector and the 
magnetic separation unit were designed as re-usable units. 
The miniaturized multi-line injection port system where dispersed nanomagnets are 
injected into the extracorporeal circuit allows for simultaneous injection of nanomagnets 
with different target specificity. This is possible via independent regulation of every 
injection line flow rate. Every line can be connected to a different stock of functionalized 
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nanomagnets. Such flexibility offers the possibility to perform tailored, patient-specific 
substance removal adjusted to different clinical settings. Using target-specific 
nanomagnets, we claim target selectivity of these magnetically tagged ligands so far 
achieved only via MDS (simultaneous and selective) (11) or FAB-coated columns 
(Glycosorb) (12, 13). Moreover, nano-sized particles show comparable contact surface 
per weight with respect to membranes or adsorptive matrixes. No pore diffusion hinders 
surface accessibility in the case of free flowing particles. Thus, the whole surface is 
readily accessible and enables uniquely fast ligand binding.  
The better purification efficiency achieved for digoxin can be explained by different 
binding characteristics (binding constant, binding kinetics, and compound concentration 
range) and different capacity of FeC-anti-digoxin and FeC-anti-IL-1β nanomagnets. The 
removal efficiency could be further optimized by increasing the number of binding sites 
per particle (achievable via optimal synthesis) and the use of antibodies with an even 
higher binding constant. Theoretical clearance was estimated assuming the reservoir as an 
ideally mixed tank (homogeneous toxin concentration distribution) and the circuit tract as 
a converter (a fixed fraction of the incoming substance is constantly converted). Although 
the model is rudimental, the theoretical values (red line) are in good agreement with the 
experimentally determined clearance dynamics. 
A further fundamental improvement in the proposed approach is represented by the 
continuity in supplying fresh adsorptive surface carrying vacant binding sites. This 
overcomes saturation of them, an inevitable event for any non-regenerating sorbent. For 
example, if non-specific adsorption takes place, media capture desired and undesired 
compounds, e.g. as observed by De Vriese et al. (14, 15) on the adsorbent Hopsal AN69: 
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anti-inflammatory compounds (i.e. IL-1 receptor antagonist) were subject to adsorption 
as much as pro-inflammatory agents were. This unfavorable fact accelerates the 
saturation process (loss of target-binding sites on the adsorbent) and thus decreases 
adsorption rates besides removing a wider class of compounds than what may be 
targeted. 
In the here-used continuous ex vivo purification setting, the major assumption, also 
previously made by Uchino et al. (16), is that a blood container is able to replicate a 
human body. This limited model can not take into account that the human body 
dynamically interacts with changes caused by extracorporeal factors, i.e. septic patients 
continuously produce cytokines (i.e. de novo synthesis) whilst undergoing therapy (2). 
The experimental conditions used in the investigated ex vivo blood purification 
experiments can be compared to real clinical dimensions (17) with potential for scale up. 
It is expected that the use of multiple lines in parallel would allow analogous extraction 
efficiencies for a patient’s whole blood volume (4.5 L) using similar conditions as in the 
ex vivo experiments shown here. Although the used transfusion sets consisted out of 
clinically approved materials, toxicity of the injected nanomagnets needs to be 
thoroughly investigated before the magnetic blood purification technology can be 
evaluated in first in vivo animal trials.  
For clinical application, biocompatibility and/or complete removal of the nanomagnets 
from blood before re-circulation are critical and ultimately determine the clinical 
applicability of the proposed approach. Various settings for high-gradient field magnetic 
separation units for efficient capturing of magnetic particles under flow conditions have 
been developed and are now being tested (9, 18, 19). Compared to commonly used 
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polymer/metal oxide beads, metal nanomagnets benefit from their higher magnetic 
moments which facilitate magnetic recovery and separation (20). Matrix effects of blood 
(high iron background) and the high chemical stability render quantification of carbon 
encapsulated iron nanomagnets complex. First experiments using water-glycerol mixtures 
with blood-like viscosity and above mentioned operating conditions (concentrations of 
particles before the separator 500 ppm, flow rate of 15 mL/min) showed that less than 4.5 
ppm iron nanomagnets were detectable after the separator (as determined by atomic 
absorption spectroscopy, see supplementary information), corresponding to a removal 
efficiency at least 99 %.  
Although first hemocompatibility tests of carbon coated nanomagnets have shown 
promising results (normal hemolysis and iron metabolism parameters, unaffected blood 
coagulation) (7), biocompatibility - with particular focus on possible interactions with the 
vascular compartment - needs to be thoroughly investigated in order to ensure a safe 
implementation of this technology (e.g. exclude the danger of embolization). 
Compatibility of the nanomagnets with the human body poses a major limitation of the 
presented blood purification device at this stage as a small amount of nanomagnets 
remains in the blood after treatment (<1%). In a next step towards clinical application, in 
vivo performance and tolerance of magnetic blood purification needs to be evaluated in 
animal models (e.g. rodent model of severe intoxication and gram-negative sepsis) to 
prove feasibility in a living organism and to gain insight into dynamic interactions of the 
organism with the blood purification device (e.g. activation of coagulation cascade or the 
complement cascade, de novo synthesis of cytokines). 
CONCLUSIONS. 
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Successful implementation of magnetic blood purification into a continuously operating 
extracorporeal device proves the feasibility of using magnetic separation for blood 
purification. Results were achieved in a first implementation of such a device already 
showing a promising capacity for treating a real patient’s blood volume in clinically 
relevant time when scaled up. It combines many favorable features that had been claimed 
in the past: high clearance rate in relatively short time frame, customization and 
potentially high selectivity towards targets and no fluid or beneficial substance loss (16, 
21-26). In clinically complex situations, e.g. sepsis and systemic inflammatory response 
syndrome (SIRS) (27), the here proposed system may offer a new tool to be added to the 
actual ones. Numerous clinically most attractive hypotheses, such as cytokine removal in 
sepsis and its effect on mortality, now remain to be proved in first animal trials. Detailed 
in vivo tests are necessary to bring magnetic separation-based blood purification closer to 
daily clinical use. 
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LEGENDS TO FIGURES. 
 
Figure 1. Magnetic separation implemented in an extracorporeal blood purification 
device (A). Nanomagnets dispersed in hydroxyethyl starch (B) are continuously injected 
into the blood stream (C). After capturing the toxins by selective capturing moieties 
immobilized on the nanomagnet surface, the toxin loaded particles are magnetically 
separated from the blood stream before the blood is recirculated into the blood reservoir. 
10 mL drip chambers were used to increase the contact time between nanomagnets and 
blood and to ensure homogeneous concentration of nanomagnets (D). 
 
Figure 2. Magnetic Separator. A schematic drawing of the distribution of nanomagnets in 
the blood flow during recollection in the magnetic separator (A). A magnetic separator 
operating under continous conditions (B). The blood purification device is passed 
multiple times through the separation unit to achieve complete separation of nanomagnets 
from blood (C).  
 
Figure 3. Magnetic blood purification under continuous conditions (A). Samples 
collected after the separator (open loop configuration) show nanomagnet-concentration 
dependent extraction of digoxin (B) and interleukin-1 (C). Subjecting the purified blood 
to a second purification cycle shows again a significant decrease in digoxin level (B). 
 
Figure 4. Continuous purification of 500 mL digoxin-spiked blood using a closed loop 
configuration where the purified blood is re-circulated to the blood reservoir after the 
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separator. A sample withdrawn directly after the separator at t = 2 min () shows the 
digoxin concentration in freshly purified blood. All other experimental points () refer to 
samples taken from the blood reservoir where the purified blood has mixed with the 
intoxicated one, as it would happen in a patient. The red curve represents calculated 
clearance dynamics assuming an ideally mixed blood reservoir and constant removal 
efficiency.  
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